CHICAGO, United States, May 30, 2025 - SeekIn Inc., a leader in blood-based cancer early detection and monitoring technology, will present cancer early detection technologies at the American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will focus on a lung cancer early detection test and a large-scale clinical validation of multi-cancer early detection test.
1. Lung cancer early detection with LungCanSeek®
SeekIn presents LungCanSeek® test, a blood-based, non-invasive, and cost-effective solution for lung cancer early detection. In a multi-cohort study involving 1,814 participants (1,095 lung cancer and 719 without cancer), the test demonstrated 83.5% sensitivity and 90.3% specificity by combining artificial intelligence (AI) algorithms with four protein tumor markers (PTMs). Additionally, LungCanSeek® provides histological subtype prediction with 77.4% accuracy, offering crucial insights to guide subsequent diagnostic and therapeutic decisions.
For optimal lung cancer screening, SeekIn recommends a two-step strategy: initial screening with LungCanSeek®, followed by low-dose computed tomography (LDCT) imaging for positive cases. This integrated approach enhances efficiency—reducing false positives by over 10-fold and cutting costs by 2.5-fold compared to sole LDCT screening in high-risk populations.
2. Large-scale clinical validation of OncoSeek® multi-cancer early detection test
Cancer is a critical global health issue, especially in low- and middle-income countries (LMICs). SeekIn addresses this need with OncoSeek®, a CE-IVD marked, blood-based multi-cancer early detection (MCED) test. Leveraging seven protein tumor markers (AFP, CA125, CA15-3, CA19-9, CA72-4, CEA, and CYFRA21-1) and AI algorithms, OncoSeek® offers an accessible, cost-effective solution at under $25 per test, requiring no additional equipment, infrastructure, or technical personnel. This affordability makes it particularly viable for the healthcare providers in LMICs.
OncoSeek® demonstrated robust performance in early detection of multiple cancers, evaluated across 15,122 participants from seven centers in three countries, utilizing four platforms and two sample types. OncoSeek® detects 14 common cancer types (accounting for 72% of global cancer deaths) with 58.4% sensitivity and 92.0% specificity, alongside 70.6% accuracy in tissue of origin (TOO) prediction. Notably, in symptomatic cohorts, the test achieved 73.1% sensitivity at 90.6% specificity, indicating OncoSeek®'s potential for early cancer diagnosis.
About 2025 ASCO
Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.
ASCO promotes and provides for lifelong learning for oncology professionals, cancer research, an improved environment for oncology practice, access to quality cancer care, a global network of oncology expertise, and educated and informed patients with cancer.